Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Have received any anti-cancer therapy within 4 weeks prior to the first dose
• •Have received a live vaccine within 30 days prior to the first dose
• •Have known primary CNS cancer.
• •Have known CNS metastases unless previously treated and well controlled for at least 1 month
• •Have concomitant second malignancies unless a complete remission was achieved at least 2 years before study entry
• •Have a history of Grade ≥ 2 pneumonitis, active autoimmune disease, or persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade ≥ 2
• •Have toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.
• •Have uncontrolled or significant cardiovascular disease
• •Part 1: major surgery within 3 weeks before initiating treatment
• •Part 1: Have received prior radiotherapy within 2 weeks of start of study treatment
• •Part 2 (H\&N cancer):
• •Have received prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
• •Have received prior chemotherapy administered in the recurrent advanced or metastatic setting (except for systemic therapy completed \> 6 months prior to screening if given as part of multimodal treatment for locally advanced disease)